HLA Typing for Transplant Market was valued at USD 330 million in 2016 and is estimated to witness 10% CAGR growth from 2018 to 2024. Hla Typing for transplant market will witness a significant growth due to increasing number of solid organ transplants across the globe. As per U.S. Department of Health and Human Services, twenty people die every day waiting for a transplant and approximately 33,611 transplants were performed in 2016. Increasing number of organ and tissue transplantation procedures in people suffering from various chronic diseases will drive the HLA typing for transplant market growth. Request for a sample of this research report -https://www.gminsights.com/request-sample/detail/1653 Technological advancements in PCR such as development of sensitive advanced assays, improved system design and high efficiency in tissue typing will further drive the industry growth. Continuous production of improved transplantation products such as surgical medical instruments, tissue typing technology and organ preservation solutions reduces organ damage during the transplant procurement, transport and implantation processes. Increasing demand for patient safety and quick post-transplant patient recovery will further fuel the demand for the HLA typing for transplantation. Significant gap between number organs required and organs donated and high costs associated with molecular devices may hamper the market growth. Strict established regulations, stringent reimbursement policies for organ transplantation and shortage of skilled professionals will further restrain the growth opportunities in the market. Molecular assays are projected to witness robust growth in the forecast period owing to increasing number of solid organ and bone marrow transplantations. Next generation sequencing provides high level of detection sensitivity, high capability of sequencing multiple markers overall low cumulative costs. Increasing utilization of next generation sequencing technologies in diagnostics and research, high-throughput DNA sequencers, rising preference for low-cost and efficient DNA sequencing technologies and wide range of applications of next generation sequencing in tissue typing will propel the segment growth. Software segment is expected to show remarkable growth during the forecast timeframe. Various technical advancements resulting in availability of version upgrades with superior and enhanced features suitable for the existing software, will increase the growth opportunities in this segment. In 2016, GenDx received CE-IVD certification for its NGSengine software that provides analysis of human leukocyte antigen (HLA) typing by next-generation sequencing on several platforms. Browse Full Report @https://bit.ly/2rL0mlp Applications of HLA typing will contribute significantly to the market due to research and development in the field of organ and tissue transplant through funds and investments by supporting organizations and private institutions. Development of innovative and advanced diagnostic tools, increasing organ transplantations and growing need for storing organs for research activities will propel the research and development segment growth. Hospital segment will grow at a rapid rate owing to the increasing number of solid organ and bone marrow transplant procedures being performed in these settings. Increasing number of hospitals in several countries due to expansion of healthcare infrastructure, favorable value-based reimbursements, increasing demand for patient wellness and better care coordination will drive the segment growth. U.S. will drive the HLA typing for transplant market in the coming years owing to the technological advancements in HLA typing, rising number of solid organ and stem cell transplantation operations, increasing public-private investments and research grants. Presence of well-established healthcare infrastructure, increasing prevalence of life threatening diseases and increasing adoption of diagnostic technologies by medical professionals will further lead to regional growth. Some of the key industry players are Thermo Fischer Scientific, Inc., Pacific Biosciences of California, Immucor, QIAGEN, Inc., Illumina, GenDx, CareDx, Abbott Laboratories and Bio-Rad Laboratories. The strategic initiatives adopted by these companies are new and innovative product launches, acquisitions and collaborations. In 2017, Immucor, Inc. launched an HLA typing assay called MIA FORA NGS FLEX that provides flexible coverage and an optimized laboratory workflow. This initiative will strengthen and expand the companys product portfolio.
This post first appeared on News, Business Market Trends, Industry Updates And More, please read the originial post: here